These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 37600956)

  • 1. Impact of HBV infection on clinical outcomes in patients with metabolic dysfunction-associated fatty liver disease.
    Cheng YM; Hsieh TH; Wang CC; Kao JH
    JHEP Rep; 2023 Sep; 5(9):100836. PubMed ID: 37600956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of concomitant hepatitis C virus infection on liver and cardiovascular risks in patients with metabolic-associated fatty liver disease.
    Tsai PS; Cheng YM; Wang CC; Kao JH
    Eur J Gastroenterol Hepatol; 2023 Nov; 35(11):1278-1283. PubMed ID: 37773778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence and clinical outcomes in subtypes of metabolic associated fatty liver disease.
    Cheng KL; Wang SW; Cheng YM; Hsieh TH; Wang CC; Kao JH
    J Formos Med Assoc; 2024 Jan; 123(1):36-44. PubMed ID: 37491179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic associated fatty liver disease better identifying patients at risk of liver and cardiovascular complications.
    Cheng YM; Wang CC; Kao JH
    Hepatol Int; 2023 Apr; 17(2):350-356. PubMed ID: 36471232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overlapping group between non-alcoholic fatty liver disease and metabolic associated fatty liver disease better for liver research.
    Cheng YM; Hsieh TH; Wang CC; Kao JH
    JGH Open; 2024 Oct; 8(10):. PubMed ID: 39403113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of all-cause mortality associated with non-alcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease in Taiwan MJ cohort.
    Cheng WC; Chen HF; Cheng HC; Li CY
    Epidemiol Health; 2024; 46():e2024024. PubMed ID: 38317531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical characteristics of lean metabolic-associated fatty liver disease and the impact of concurrent diabetes mellitus.
    Cheng YM; Wang SW; Wang CC; Kao JH
    Tzu Chi Med J; 2024; 36(4):425-432. PubMed ID: 39421499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver fibrosis is closely related to metabolic factors in metabolic associated fatty liver disease with hepatitis B virus infection.
    Lv H; Jiang Y; Zhu G; Liu S; Wang D; Wang J; Zhao K; Liu J
    Sci Rep; 2023 Jan; 13(1):1388. PubMed ID: 36697471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Analysis of clinical characteristics and risk factors of hepatic fibrosis in children with chronic hepatitis B combined with metabolic-related fatty liver disease].
    Li W; Jiang LN; Zhao BK; Liu HY; Zhao JM
    Zhonghua Gan Zang Bing Za Zhi; 2023 Jun; 31(6):601-607. PubMed ID: 37400384
    [No Abstract]   [Full Text] [Related]  

  • 10. [Analysis of clinical and pathological features of chronic hepatitis B combined with metabolic-associated fatty liver disease].
    Shang MY; Chen YZ; Bao J; Tong YL
    Zhonghua Gan Zang Bing Za Zhi; 2023 Feb; 31(2):126-132. PubMed ID: 37137826
    [No Abstract]   [Full Text] [Related]  

  • 11. Metabolic-associated fatty liver disease in relation to site-specific and multiple-site subclinical atherosclerosis.
    Wang X; Zhang R; Man S; Lv J; Yu C; Yin J; Wang X; Deng Y; Wang B; Li L; Pang Y
    Liver Int; 2023 Aug; 43(8):1691-1698. PubMed ID: 37337780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinic-pathological features of metabolic associated fatty liver disease with hepatitis B virus infection.
    Wang MF; Wan B; Wu YL; Huang JF; Zhu YY; Li YB
    World J Gastroenterol; 2021 Jan; 27(4):336-344. PubMed ID: 33584066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B.
    van Kleef LA; Choi HSJ; Brouwer WP; Hansen BE; Patel K; de Man RA; Janssen HLA; de Knegt RJ; Sonneveld MJ
    JHEP Rep; 2021 Oct; 3(5):100350. PubMed ID: 34557660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The progression and regression of metabolic dysfunction-associated fatty liver disease are associated with the development of subclinical atherosclerosis: A prospective analysis.
    Liu S; Wang J; Wu S; Niu J; Zheng R; Bie L; Xin Z; Wang S; Lin H; Zhao Z; Wang T; Xu M; Lu J; Chen Y; Xu Y; Wang W; Ning G; Bi Y; Li M; Xu Y
    Metabolism; 2021 Jul; 120():154779. PubMed ID: 33895182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibrosis-4 Index Score Predicts Concomitant Coronary Artery Diseases Across the Spectrum of Fatty Liver Disease.
    McNally BB; Rangan P; Wijarnpreecha K; Fallon MB
    Dig Dis Sci; 2023 Sep; 68(9):3765-3773. PubMed ID: 37392337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic dysfunction-associated fatty liver disease increased the risk of subclinical carotid atherosclerosis in China.
    Lei F; Wang XM; Wang C; Huang X; Liu YM; Qin JJ; Zhang P; Ji YX; She ZG; Cai J; Li HP; Zhang XJ; Li H
    Front Endocrinol (Lausanne); 2023; 14():1109673. PubMed ID: 37082131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MAFLD Criteria May Overlook a Subtype of Patient with Steatohepatitis and Significant Fibrosis.
    Huang J; Xue W; Wang M; Wu Y; Singh M; Zhu Y; Kumar R; Lin S
    Diabetes Metab Syndr Obes; 2021; 14():3417-3425. PubMed ID: 34349535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The metabolic profiles and body composition of non-obese metabolic associated fatty liver disease.
    Zhang Y; Xiang L; Qi F; Cao Y; Zhang W; Lv T; Zhou X
    Front Endocrinol (Lausanne); 2024; 15():1322563. PubMed ID: 38375190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and Histologic Features of Patients with Biopsy-Proven Metabolic Dysfunction-Associated Fatty Liver Disease.
    Huang SC; Su HJ; Kao JH; Tseng TC; Yang HC; Su TH; Chen PJ; Liu CJ
    Gut Liver; 2021 May; 15(3):451-458. PubMed ID: 33431715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A significant risk of metabolic dysfunction-associated fatty liver disease plus diabetes on subclinical atherosclerosis.
    Bessho R; Kashiwagi K; Ikura A; Yamataka K; Inaishi J; Takaishi H; Kanai T
    PLoS One; 2022; 17(5):e0269265. PubMed ID: 35639744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.